RANCHO CORDOVA, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, announced today a new integrated distribution agreement in Europe with Concessus for its cord blood products—the AXP ® AutoXpress ® (AXP) System and BioArchive ® System.
The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems and the BioArchive System is an automated robotic device for cryopreserving and archiving cord blood stem cell units for transplant.
Under the four-year agreement, Concessus will distribute both the AXP and BioArchive in the following countries: France, Spain, Switzerland, Benelux, Liechtenstein and Nordic countries (excluding Iceland). Concessus, which has been distributing the BioArchive since 2010, is a nearly 50-year-old Lisbon-based company that has been involved in the cord blood market for more than two decades. Concessus specializes in equipment for the healthcare diagnostic laboratory and research markets, with a strong focus on key markets in Western Europe.GE Healthcare, which had been distributing the AXP in these markets, will continue to distribute the offering in the U.S. and Canada. "This is an important development in our market expansion strategy as it represents a customer-centric approach that incorporates marketing, service and support for both of our cord blood products with one channel partner. We believe this agreement, in concert with our leading-edge technology, will not only strengthen our relationships with existing customers, but also enhance our competitive position in these important geographies," said Hal Baker, Head of Commercial Operations for ThermoGenesis. "Representing the AXP now together with the BioArchive in Western Europe creates a meaningful competitive advantage for us in the cord blood market," said João Araújo, Chief Executive Officer of Concessus. "We are now the only organization in Western Europe offering fully automated cell processing and cell storage products and services for the cord blood market," he continued.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts